Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
07:30am, Monday, 25'th Mar 2024
– Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2nd line AML subjects – AnnAraC has potential to fill significant unmet need and expected
Moleculin Reports Full Year 2023 Financial Results
04:05pm, Friday, 22'nd Mar 2024
– Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and web
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
07:30am, Wednesday, 20'th Mar 2024
In-depth discussion of stratification of Company's 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of
Moleculin to Present at the 36th Annual ROTH Conference
09:05am, Tuesday, 12'th Mar 2024
Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmace
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
12:02pm, Tuesday, 14'th Nov 2023
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
08:45am, Tuesday, 07'th Nov 2023
HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinic
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
09:01am, Friday, 22'nd Sep 2023
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?
08:24am, Friday, 15'th Sep 2023
Moleculin Biotech (NASDAQ: MBRX ) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors. According to a press release from Moleculin Biotech, the
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:35am, Tuesday, 05'th Sep 2023
HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clini
Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript
10:08am, Friday, 11'th Aug 2023
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO John Paul Waymack - Senior CMO
Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast
08:45am, Thursday, 03'rd Aug 2023
HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
08:35am, Tuesday, 13'th Jun 2023
Live webcast fireside chat on Wednesday, June 21 st at 1:30 PM ET HOUSTON , June 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmac
Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript
11:29am, Thursday, 11'th May 2023
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Offi
MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates
08:04am, Thursday, 11'th May 2023
Moleculin Biotech (NASDAQ: MBRX ) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents.
Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
08:35am, Thursday, 04'th May 2023
HOUSTON , May 4, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
